The company will use the cash infusion to expand its international market presence, with an emphasis on the US and Japan, where it is seeking regulatory approval for a number of multiplex PCR-based diagnostic tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.